Table 1 Baseline characteristics of study cohort, stratified by EVI1 protein expression
Category | All | EVI1 low (≤ 30%) | EVI1 high(> 30%) | p-value | |
|---|---|---|---|---|---|
All | Â | 562 (100.0) | 130 (23.1) | 432 (76.9) | -- |
Age | ≤ 60 | 263 (48.0) | 54 (43.2) | 209 (49.4) | 0.262 |
>60 | 285 (52.0) | 71 (56.8) | 214 (50.6) | Â | |
missing | 14 (2.5) | Â | Â | Â | |
Tumor stage | pT1 | 37 (6.7) | 4 (3.2) | 33 (7.7) | 0.123 |
pT2 | 40 (7.2) | 7 (5.6) | 33 (7.7) | Â | |
pT3 | 475 (86.1) | 114 (91.2) | 361 (84.6) | Â | |
missing | 10 (1.8%) | Â | Â | Â | |
Nodal stage | pN0 | 145 (32.3) | 37 (36.3) | 108 (31.1) | 0.400 |
pN+ | 304 (67.7) | 65 (63.7) | 239 (68.9) | Â | |
missing | 113 (20.1%) | Â | Â | Â | |
FIGO group | FIGO I | 29 (5.2) | 4 (3.2) | 25 (5.8) | 0.072 |
FIGO II | 28 (5.0) | 5 (4.0) | 23 (5.4) | Â | |
FIGO III | 392 (70.8) | 88 (69.8) | 304 (71.0) | Â | |
FIGO IV | 105 (19.0) | 29 (23.0) | 76 (17.8) | Â | |
missing | 8 (1.4) | Â | Â | Â | |
PARP1 | Low (≤ 45%) | 266 (56.8) | 70 (66.0) | 196 (54.1) | 0.019 |
High (> 45%) | 202 (43.2) | 36 (34.0) | 166 (45.9) | Â | |
missing | 94 (16.7) | Â | Â | Â | |
Chemotherapy | Platinum + Taxol | 413 (94.3) | 89 (94.7) | 324 (94.2) | 0.984 |
Platinum + other | 6 (1.4) | 1 (1.1) | 5 (1.5) | Â | |
Platinum alone | 13 (3.0) | 3 (3.2) | 10 (2.9) | Â | |
Other | 1 (0.2) | 0 (0) | 1 (0.3) | Â | |
No chemotherapy | 5 (1.1) | 1 (1.1) | 4 (1.2) | Â | |
missing | 124 (22.1) | Â | Â | Â | |